BillionToOne publishes immunotherapy ctDNA monitoring research presentation

BillionToOne

BLLN

0.00

Billiontoone Inc. released research on using serial ctDNA methylation dynamics to flag molecular progression in ICI-treated solid tumors.
In a 65-patient cohort, serial-sampling molecular progression showed stronger separation than single-timepoint cutoffs; PFS HR 5.3; OS HR 4.9.
An independent 72-patient pan-cancer cohort reproduced results; PFS HR 4.6; OS HR 4.3 across immunotherapy regimens.
Longitudinal monitoring signaled progression about 77 days before clinical progression, 63.5 days before RECIST-based progression.
Among RECIST 6-month non-progressors, molecular progression flagged about 20% with worse outcomes, supporting earlier treatment changes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.